Ebola outbreak in the Democratic Republic of Congo reaches two more health zones

The Democratic Republic of Congo’s Ebola outbreak has spread to two additional health zones, extending the reach of a rapidly expanding epidemic across the country’s north and east.

The newly affected areas are Bulu in South Ubangi, near the border with the Central African Republic, and Dungu in Haut-Uele, near South Sudan, according to reporting by Al Jazeera and Reuters citing the World Health Organization. The two additions bring the number of affected health zones to 63 across seven provinces. (aljazeera.com)

The outbreak is caused by the Bundibugyo virus, a less-studied Ebola species. WHO data cited in the report showed that, as of September 23, the DRC had recorded 7,890 confirmed cases and 3,799 deaths. The figures indicate a reported case-fatality ratio of about 48%, although the totals may change as surveillance, laboratory testing and data reconciliation continue. (aljazeera.com)

Geographic expansion increases response pressure

Ituri remains the outbreak’s main centre, with 6,032 confirmed cases reported since the epidemic began in May, according to the WHO figures cited by Al Jazeera. North Kivu is the second most affected province and has recorded a rising share of recent cases and deaths. (aljazeera.com)

WHO officials have said that armed conflict, population displacement and difficulty reaching some communities are complicating contact tracing and access to care. The Africa Centres for Disease Control and Prevention has also warned that the number of people listed as contacts is far below the level expected from an outbreak of this size, according to the same report. (aljazeera.com)

The geographic picture has changed quickly. In a WHO disease-outbreak update based on data to September 7, the epidemic had reached 61 health zones across six provinces, with Kayna in North Kivu the latest area then recorded. The later addition of Bulu and Dungu marks a further expansion beyond that earlier count. (who.int)

Vaccination and treatment remain under study

WHO says there is no licensed vaccine specifically approved for Bundibugyo virus disease. The organisation has recommended that the existing Ervebo vaccine be used only within research protocols while clinical evidence is gathered. A treatment trial, known as PARTNERS, is under way in treatment facilities in Ituri. (who.int)

WHO’s latest available risk assessment places the risk within the DRC at very high, the risk to countries sharing land borders at high, and the global risk at low. The agency has advised against travel or trade restrictions while calling for stronger surveillance, cross-border coordination and rapid case detection. (who.int)

What remains unclear from the available reports is how many cases have been confirmed in Bulu and Dungu, whether the infections are linked to known transmission chains, and whether additional health zones have been affected since the September 23 count.

The next key indicators will be updated case totals from Congolese health authorities and WHO, the results of contact-tracing operations in the two newly affected zones, and evidence of whether transmission is accelerating in border communities.

Africa & Beyond — News | Analysis | Perspective